The first participant in a clinical trial for a vaccine to protect against the new coronavirus will receive an experimental dose Monday, according to a government official.The National Institutes of Health is funding the trial, which is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle. The official who disclosed plans for the first participant spoke on condition of anonymity because the move has not been publicly announced.Public health officials say it will take a year to 18 months to fully validate any potential vaccine.Testing will begin with 45 young, healthy volunteers with different doses of shots co-developed by NIH and Moderna Inc. There’s no chance participants could get infected from the shots, because they don’t contain the virus itself. The goal is purely to check that the vaccines show no worrisome side effects, setting the stage for larger tests.Dozens of research groups around the world are
Upstate News Headlines
- Trevor Lawrence set for possibly his final Clemson home game
- Fox News Is Terrified of Trump Supporters (and They Should Be)
- TV Rewind: Why Skins Remains a Gold Standard for Teen Drama Series
- The Croods: A New Age Is Hardly an Evolution from the Original, but Still Finds Laughs
- Make your predictions for Sunday's game at Minnesota
- Pickin' It: Panthers at Vikings
- Notre Dame vs. North Carolina: 2020 Game Preview
- DHEC to offer free HIV testing for World AIDS Day
- Teen Driver Charged after Deadly DUI Crash in Anderson Co.
- 1 dead after 3-vehicle DUI Crash in Spartanburg Co.